HCPCS A9607
Lutetium lu 177 vipivotide tetraxetan, therapeutic, 1 millicurie (CMS descriptor)
Other services Work RVU per service none (2024 fee schedule; adds 0 work RVUs)
Trend
Medicare payment on the code
Source: CMS Medicare Physician & Other Practitioners public use files (Original Medicare Part B fee-for-service). Data years 2022–2024.
Billers
Source: CMS Medicare Physician & Other Practitioners public use files (Original Medicare Part B fee-for-service). Data years 2022–2024.
| observed | calculated | calculated | calculated | calculated | calculated | reported | |
|---|---|---|---|---|---|---|---|
| 2024 | 31 | $61,252,060 | -28% | 301,011 | 7,000 | 25,277 | 0.00 |
| 2023 | 44 | $84,920,922 | +616% | 430,015 | 7,568 | 22,938 | 0.00 |
| 2022 | 12 | $11,863,235 | not in the 2021 file | 60,063 | 4,365 | 8,743 |
Source: CMS Medicare Physician & Other Practitioners public use files (Original Medicare Part B fee-for-service). Data years 2022–2024.
By state
No state has a reportable line for A9607 in 2024.
Top metro areas
No metro area has a reportable line for A9607 in 2024.
Specialties billing A9607 nationally
Radiation Oncology accounts for 39% of payment for A9607 nationally in 2024, across 1 specialties on claims.
| observed | calculated | calculated | calculated | calculated | calculated | |
|---|---|---|---|---|---|---|
| Radiation Oncology | 12 | 39% | $23,711,389 | 39% | 115,886 | 9,657 |
Not listed: 3 specialties with fewer than 11 billers (small cells).
Source: CMS Medicare Physician & Other Practitioners public use files (Original Medicare Part B fee-for-service). Provider-level lines (fewer than 11 beneficiaries suppressed by CMS); specialty is the provider type on claims. Data year 2024.
Top billers of A9607 nationally
Named top billers are a Pro figure, and Pro is not available to buy, so this list is not shown to any account. The counts and totals by state, metro area and specialty on this page are free.
Original Medicare Part B fee-for-service only; CMS suppresses provider lines with fewer than 11 beneficiaries. How these figures are computed · Limitations